Seattle Genetics Earnings Conference Call (Q3 2009)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Oct 22 Calls Today's Calls

Call Details Seattle Genetics Earnings Conference Call (Q3 2009) Thu, Oct 22, 2009, 5:00 pm Eastern Listen to the archived event audio About Seattle Genetics (NasdaqGM:SGEN) Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma under a special protocol assessment. The company’s other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; and SGN-70, a humanized anti-CD70 antibody. In addition, its product candidates in development comprise SGN-75 for CD70-positive hematologic malignancies and solid tumors; AGS-5ADC for solid tumors; and SGN-19A for CD19-positive hematologic malignancies. It has a collaboration agreement with Genentech, Inc. to develop and commercialize Dacetuzumab; with Genentech, Inc., Bayer Pharmaceuticals Corporation, CuraGen Corporation, Progenics Pharmaceuticals, Inc., Daiichi Sankyo Co., Ltd., and MedImmune Inc. for the company’s antibody-drug conjugates (ADC) technology; and an ADC co-development agreement with Agensys, Inc. The company was founded in 1997 and is headquartered in Bothell, Washington. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Analyst Ratings